Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xeruborbactam + cefiderocol
- Development stage
- Unknown
- Lead developer
- Qpex Biopharma
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Xeruborbactam + cefiderocol is an investigational combination therapy targeting multidrug-resistant Gram-negative bacterial infections. Cefiderocol is a siderophore cephalosporin antibiotic that utilizes iron transport channels to enter bacterial cells and inhibits penicillin-binding proteins, thereby blocking cell wall synthesis and causing bacterial death. Xeruborbactam is a novel, ultra-broad-spectrum boron-based beta-lactamase inhibitor that inactivates both serine-type and metallo-beta-lactamases, enzymes responsible for resistance to many beta-lactams. The combination aims to restore or enhance the activity of cefiderocol against bacteria producing these resistance enzymes, including carbapenem-resistant strains such as *Acinetobacter baumannii* and *Enterobacterales*. This combination is being developed by Qpex Biopharma (a Shionogi Group company) with support from BARDA for the treatment of serious drug-resistant Gram-negative infections[1][2][4].
- Other names
- Cefiderocol/Xeruborbactam
02
Targets
PBP2 (Penicillin-binding protein 2)PBP1b (Penicillin-binding protein 1B)β-lactamasePBP1A (Penicillin-binding protein 1A)Neuraminidase
Beyond the preview
Go deeper on xeruborbactam + cefiderocol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xeruborbactam + cefiderocol.